UW21125
OPEN TO ACCRUAL
Ph 1 Study of GS-1811 alone and with Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors
EAY191
OPEN TO ACCRUAL
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
EAY191E5
OPEN TO ACCRUAL
A Randomized Phase II Study of AMG 510 (Sotorasib) with or without Panitumumab in Advanced Solid Tum
NCI10397
OPEN TO ACCRUAL
Ph 2 Study Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)
NCI10528
OPEN TO ACCRUAL
PH1 Study of (POL0) in BRCA-mutant and other DNA Damage Repair-Deficient Solid Tumors
UW22117
OPEN TO ACCRUAL
PH1b Continuing Treatment for Participants who Participated in Prior Protocol with CC-122
UW22141
OPEN TO ACCRUAL
PH1/2 Study of IMC-F106C as Monotherapy/Combination w/Checkpoint Inhibitors in PRAME-Positive Cancer
UW23053
OPEN TO ACCRUAL
PH1 Study of KO-2806 Administered as Monotherapy & in Combination in Adults w/ Advanced Solid Tumors
UW23126
OPEN TO ACCRUAL
A Phase 1a/1b Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
UW23136
OPEN TO ACCRUAL
PH1 Study ASP1570 & Combo w/ Pembrolizumab or SOC in pts w/ Locally Advanced or Metastatic Tumors
UW24012
OPEN TO ACCRUAL
Ph 1b/2 Study of Disitamab Vedotin alone and with Other Anticancer Therapies in Solid Tumors
UW24096
OPEN TO ACCRUAL
A Phase 1a/1b Trial of LY3962673 in Participants w/ KRAS G12D-Mutant Solid Tumors
UW24120
OPEN TO ACCRUAL
PH 1/1B Study of ALTA2618 in PTS w/ Advanced Solid Tumors W/ AKT1 E17K Mutation
UW24140
OPEN TO ACCRUAL
A Ph 1/2 Study of STAR0602 in Subjects with Solid Tumors that are Antigen-rich
UW24144
OPEN TO ACCRUAL
A LTFU Basket Study for Patients Treated with SynKIR CAR T Cell Product
UW24148
OPEN TO ACCRUAL
A Ph 2 Study of BAY 2927088 in Pts w/ Solid Tumors w/ HER2-Activating Mutations
UW24149
OPEN TO ACCRUAL
Ph1a/b Study of BG-C137 Targeting FGFR2b in Patients w/ Advanced Solid Tumors
UW25006
OPEN TO ACCRUAL
Ph 1 Study of PF-07985045 as a Single Agent or in Combo w/ Other Agents in Pts w/ Solid Tumors
UW25018
OPEN TO ACCRUAL
A Phase 1/2 Study of FOG-001 in Participants with Locally Advanced or Metastatic Solid Tumors